Arcus biosciences reports second-quarter 2023 financial results and provides a pipeline update

Hayward, calif.--(business wire)--arcus biosciences, inc. (nyse:rcus), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today reported financial results for the second quarter ended june 30, 2023, and provided a pipeline update on its clinical-stage investigational molecules – targeting tigit, the adenosine axis (cd73 and a2a/a2b receptors), hif-2a and pd-1 – across multiple common cancers. “beyon.
RCUS Ratings Summary
RCUS Quant Ranking